$SGRP

SPAR Group SGRP Q4 2025 Earnings Transcript

SPAR Group reported full-year 2025 net revenue of $136.1 million, up 3.3%, with U.S. revenue at $122.1 million (+3.9%) and Canada flat at $14.1 million. Gross profit fell to $21.7 million (15.9% margin). The company posted a net loss of $24.6 million ($1.04/share) and adjusted net loss of $10.7 million ($0.45/share). It completed exiting non–U.S./Canada joint ventures, launched a ReposiTrak AI partnership, and guided 2026 revenue to $143–$151 million with gross margin of 20.5%–22.5%.

Original reporting
Published Jun 8, 2026, 7:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 7:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SPAR Group SGRP Q4 2025 Earnings Transcript — source image
Decision brief

The 30-second read

$SGRPNeutralMed
01

Why it matters

FY2025 results show severe margin compression and restructuring costs, while 2026 guidance targets revenue growth and gross margin expansion via a service-mix pivot (more merchandising vs. remodel) and normalized SG&A excluding nonrecurring items.

02

Market read

Traders can update models using the disclosed FY2025 loss drivers and the explicit 2026 revenue and gross margin targets, while stress-testing recovery timing against cash burn and negative EBITDA.

03

What to watch

Operating cash used by operations ($18.4M) and negative EBITDA suggest working-capital and execution discipline could be the binding constraint, not just gross margin or SG&A run-rate.

Relevance 9/10Novelty 8/10Timing: Post-earnings transcript; use for positioning ahead of Q1 2026 normalization commentary.

Background

SPAR Group is executing a transformation: exiting international joint ventures, shifting from labor-based hours to outcome-based tech-enabled field execution, and partnering for AI-driven out-of-stock detection.

Company-level read

Ticker impact

$SGRPNeutralMedium confidence
Context

SPAR Group reported FY2025 net loss and guided 2026 revenue $143M-$151M with gross margin 20.5%-22.5% after transformation costs.

Expected impact

Likely choppy reaction: investors may buy the 2026 margin/revenue recovery narrative but remain cautious on operating loss and operating cash outflows.

Evidence & confidence

The transcript discloses both deteriorated FY profitability (operating loss, negative EBITDA) and forward-looking targets tied to mix shift away from remodels plus SG&A normalization; cash used by operations adds downside risk to the timing of recovery.

Market effects

Highlights a shift toward tech-enabled, outcome-based retail execution and AI inventory visibility partnerships, which may influence competitive expectations for service providers.

Focus on U.S. and Canada simplifies operations and could concentrate demand/contracting activity in North America.

Limited, as management exited non-North America joint ventures and frames growth around North America-only execution.

Counterpoint

Margin recovery may be slower than guided if wage pressure and transformation-related inefficiencies persist beyond the expected normalization window.

Key entities

  • SPAR Group, Inc.

    Reported FY2025 net loss and provided 2026 revenue and gross margin guidance tied to transformation and service-mix changes.

  • William Linnane

    CEO who discussed the outcome-based, AI-enabled retail execution model and margin recovery path.

  • Steven Hennen

    CFO who attributed gross margin compression to higher labor/travel costs, wage pressure, and remodeling mix.

  • ReposiTrak

    AI-enabled inventory visibility/out-of-stock detection and logistics partner described as live for on-demand merchandising.

Related articles

$MURMedAI 8/10

Murphy Oil Sees Sharp Profit Increase

Murphy Oil Corp reported Q2 2026 adjusted net income of $225.8 million, nearly six times Q2 2025, as higher oil prices offset lower production and weaker gas. Adjusted EPS was $1.55 vs $1.51 consensus. Revenue rose to $926.3 million. Murphy kept its $0.35 dividend and raised 2026 capex midpoint to $1.55 billion.

$GSBDMed

Goldman Sachs BDC Q2 Earnings Call Highlights

Goldman Sachs BDC (NYSE:GSBD) reported no incentive fee in Q2, citing its three-year total-return lookback provision. NAV was $12.06/share at June 30 vs $12.17 in Q1. The board declared a Q3 base dividend of $0.32/share plus $0.03 supplemental. Investments were $3.2B fair value, non-accrual 2.9%, and net debt-to-equity 1.35x.

$HBBMed

Hamilton Beach Brands Q2 Earnings Call Highlights

Hamilton Beach Brands (HBB) reported Q2 gross margin of 26.1% excluding tariff-related benefits, and said it expects 2026 revenue growth in the mid-single-digit range. Management forecast full-year gross margin to improve modestly and operating profit to decline by a high-single-digit percentage. Operating cash flow is expected at $35M to $45M. HBB ended with net cash of $51.5M.

$GXOMed

GXO Logistics Q2 Earnings Call Highlights

GXO Logistics reported Q2 results and said it secured over $1 billion in expected incremental new-business revenue for 2026 and about $353 million for 2027. Management cited a $2.7 billion sales pipeline after quarter end. Operating cash flow was $76 million, free cash flow positive $12 million, cash $769 million, and net leverage 2.6x. GXO plans to target EBIT margins above 6% and deploy AI across ~50 sites in 2026.

$GRNDMed

Grindr Q2 Earnings Call Highlights

Grindr (NYSE:GRND) said free users remain central to its strategy, while AI tools are boosting engineering productivity. Management estimated engineering output rose about 2.5x from July 2025 to April 2026 with similar headcount, supporting a 39% to 42% adjusted EBITDA margin outlook. EDGE AI premium tier rollout is planned for later in fall; operating expenses ex cost of revenue were $71M vs $53M.

$HAEMedAI 8/10

Haemonetics Q1 Earnings Call Highlights

Haemonetics (NYSE:HAE) reported Q1 interventional technologies returning to 3% organic growth, with vascular closure led by VASCADE MVP and MVP XL momentum in the U.S. Apheresis revenue rose 6% organically to $191M and plasma revenue grew 8% organically as Persona PLUS rollout accelerates. Haemonetics raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic.